Sugi Predict

Sugi Predict / Compounds / SCHEMBL1012270

SCHEMBL1012270

SCHEMBL1012270

COC(=O)c1cc(OC)c(OCCCCl)cc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.52
▸ HTT P42858 1/20 0.52
▸ NPC1 O15118 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ LMNA P02545 4/20 0.49
▸ PKM P14618 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ MAPT P10636 1/20 0.46
▸ CASP3 P42574 1/20 0.45
▸ SENP8 Q96LD8 1/20 0.45
▸ SENP7 Q9BQF6 1/20 0.45
▸ SENP6 Q9GZR1 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1011872 1.00 POLB (0.52) POLBHTTNPC1CYP3A4LMNA
SCHEMBL25040483 0.96 POLB (0.51) POLBHTTNPC1CYP3A4LMNA
SCHEMBL4372581 0.96 POLB (0.51) POLBHTTNPC1CYP3A4LMNA
SCHEMBL1012564 0.95 POLB (0.52) POLBHTTNPC1CYP3A4LMNA
SCHEMBL1012714 0.95 POLB (0.52) POLBHTTNPC1CYP3A4LMNA
SCHEMBL2149235 0.93 HTT (0.55) POLBHTTNPC1CYP3A4LMNA
SCHEMBL14705129 0.93 HTT (0.55) POLBHTTNPC1CYP3A4LMNA
SCHEMBL5964493 0.92 POLB (0.54) POLBHTTNPC1CYP3A4LMNA
SCHEMBL14418100 0.90 HTT (0.55) POLBHTTNPC1CYP3A4LMNA
SCHEMBL28400061 0.90 POLB (0.52) POLBHTTNPC1CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114409636-B Quinazolinone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 沈阳药科大学 2023-04-18 — — CN claimed
CN-114409636-B Quinazolinone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 沈阳药科大学 2023-04-18 — — CN disclosed
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-02-21 — — US disclosed
EP-2956138-B1 THERAPEUTIC COMPOUNDS AND USES THEREOF KALA PHARMACEUTICALS INC (US) 2022-06-22 — — EP disclosed
CN-114409636-A Quinazolinone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 沈阳药科大学 2022-04-29 — — CN disclosed
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 — — US disclosed
US-20210393641-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF OXFORD FINANCE LLC 2021-12-23 — — US disclosed
CN-106083836-B H based on quinazoline structure2S donor compound and application thereof 徐州医学院 2021-08-20 — — CN disclosed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 — — EP disclosed
US-10966987-B2 Therapeutic compounds and uses thereof KALA PHARMACEUTICALS, INC. (US) 2021-04-06 — — US disclosed
EP-0973746-B1 SUBSTITUTED 3-CYANO QUINOLINES WYETH CORP (US) 2003-09-24 — — EP disclosed
EP-1263503-A2 USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS AMERICAN CYANAMID COMPANY (US) 2002-12-11 — — EP disclosed
US-6384051-B1 ANTITUMOR AGENTS AMERICAN CYANAMID COMPANY 2002-05-07 — — US disclosed
WO-2001068186-A2 USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS AMERICAN CYANAMID COMPANY (US) 2001-09-20 — — WO disclosed
US-6288082-B1 COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE AMERICAN CYANAMID COMPANY 2001-09-11 — — US disclosed
EP-1117659-A1 SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS American Cyanamid Company (US) 2001-07-25 — — EP disclosed
WO-2000018761-A1 SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-04-06 — — WO disclosed
EP-0973746-A1 SUBSTITUTED 3-CYANO QUINOLINES American Cyanamid Company (US) 2000-01-26 — — EP disclosed
US-6002008-A Substituted 3-cyano quinolines AMERICAN CYANAMID COMPANY 1999-12-14 — — US disclosed
WO-1998043960-A1 SUBSTITUTED 3-CYANO QUINOLINES AMERICAN CYANAMID COMPANY (US) 1998-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10966987-B2 Therapeutic compounds and uses thereof MUC1, CFTR, SLC26A4 POLB 3236/4885HTT 972/4885NPC1 10/4885
US-20210393641-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF MUC1, CFTR, SLC26A4 POLB 3236/4885HTT 972/4885NPC1 10/4885
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 POLB 871/4885HTT 293/4885NPC1 2468/4885
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 POLB 884/4885HTT 291/4885NPC1 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.